Cargando…

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment

OBJECTIVE: We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance. METHODS: From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tur, Carmen, Tintoré, Mar, Vidal-Jordana, Ángela, Bichuetti, Denis, Nieto González, Pablo, Arévalo, María Jesús, Arrambide, Georgina, Anglada, Elisenda, Galán, Ingrid, Castilló, Joaquín, Nos, Carlos, Río, Jordi, Martín, María Isabel, Comabella, Manuel, Sastre-Garriga, Jaume, Montalban, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858305/ https://www.ncbi.nlm.nih.gov/pubmed/24340060 http://dx.doi.org/10.1371/journal.pone.0082796

Ejemplares similares

Lesion topographies in multiple sclerosis diagnosis: A reappraisal
por: Arrambide, Georgina, et al.
Publicado: (2017)

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis
por: Zuluaga, María I., et al.
Publicado: (2019)

The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS
por: Tintore, Mar, et al.
Publicado: (2019)

Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
por: Tur, Carmen, et al.
Publicado: (2022)

Neurofilament light chain level is a weak risk factor for the development of MS
por: Arrambide, Georgina, et al.
Publicado: (2016)

Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials
por: Vidal-Jordana, Angela, et al.
Publicado: (2021)

Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis
por: Otero-Romero, Susana, et al.
Publicado: (2021)

Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2022)

Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2022)

Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI
por: Coll, Llucia, et al.
Publicado: (2023)

Predictive value of early brain atrophy on response in patients treated with interferon β
por: Pérez-Miralles, Francisco Carlos, et al.
Publicado: (2015)

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients
por: Carvajal, René, et al.
Publicado: (2023)

Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2015)

Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis
por: Zabalza, Ana, et al.
Publicado: (2022)

T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations
por: Boaventura, Mateus, et al.
Publicado: (2022)

An expert patient program to improve the empowerment and quality of life of people with multiple sclerosis: protocol for a multicenter pre-post intervention study
por: Robles-Sanchez, Miguel Angel, et al.
Publicado: (2023)

Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis
por: Arrambide, Georgina, et al.
Publicado: (2013)

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles
por: de la Hera, Belén, et al.
Publicado: (2014)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Aggressive multiple sclerosis (1): Towards a definition of the phenotype
por: Iacobaeus, Ellen, et al.
Publicado: (2020)

Aggressive multiple sclerosis (2): Treatment
por: Arrambide, Georgina, et al.
Publicado: (2020)

Detection of lesions in the optic nerve with magnetic resonance imaging using a 3D convolutional neural network
por: Martí-Juan, Gerard, et al.
Publicado: (2022)

CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
por: Comabella, Manuel, et al.
Publicado: (2021)

Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis
por: Cantó, Ester, et al.
Publicado: (2014)

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice
por: Sastre-Garriga, Jaume, et al.
Publicado: (2020)

Revista de Neurología cumple medio siglo
por: Sastre-Garriga, Jaume
Publicado: (2023)

Fármacos modificadores de la enfermedad en la esclerosis múltiple durante la lactancia: revisión de la evidencia actual
por: Sánchez-Velasco, Sara, et al.
Publicado: (2023)

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
por: Fernández, O., et al.
Publicado: (2012)

Multiple sclerosis management during the COVID-19 pandemic
por: Moss, Brandon P, et al.
Publicado: (2020)

Cross-Country Adaptation of a Psychological Flexibility Measure: The Comprehensive Assessment of Acceptance and Commitment Therapy Processes
por: Giovannetti, Ambra Mara, et al.
Publicado: (2022)

Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta
por: Bustamante, Marta F., et al.
Publicado: (2013)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Diagnostic challenge in children with an acquired demyelinating syndrome: an illustrative case report
por: Midaglia, Luciana, et al.
Publicado: (2023)

Chitinases and chitinase-like proteins as biomarkers in neurologic disorders
por: Pinteac, Rucsanda, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7057alcnnfr7n1cpj8gh222ies